Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1D2O0)

• Drug Name: KML-001 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 60356606
  TTD Drug ID: DM1D2O0

Molecule-Related Drug Atlas

Drug(s) Targeting Telomerase reverse transcriptase (TERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Berberine	DMC5Q8X	N. A.	N. A.	Phase 4	[3]
GV1001	DMHULRK	Pancreatic cancer	2C10	Phase 3	[4]
Imetelstat	DMONWJ4	Myelodysplastic syndrome	2A37	Phase 2/3	[5]
VM1500A	DM9YSSY	Human immunodeficiency virus-1 infection	1C62	Phase 2/3	[6]
Dendritic cell vaccine	DML4PMG	Ovarian cancer	2C73	Phase 2	[7]
GRNVAC1	DMAHOEP	Acute myeloid leukaemia	2A60	Phase 2	[8]
Vx-001	DMDKWA3	Breast cancer	2C60-2C65	Phase 2	[9]
CB-10-01	DM2IFYZ	Melanoma	2C30	Phase 2	[10]
Epithalon	DMWSGZU	Ocular inflammation	9C61.24	Phase 1/2	[11]
OBP-301	DM9MF08	Breast cancer	2C60-2C65	Phase 1/2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Telomerase reverse transcriptase (TERT)	TTUJFD0	TERT_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT01110226) Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies. U.S. National Institutes of Health.
• [2] National Cancer Institute Drug Dictionary (drug id 672554).
• [3] Stage specificity of Plasmodium falciparum telomerase and its inhibition by berberine. Parasitol Int. 2002 Mar;51(1):99-103.
• [4] Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer. 2006 Dec 4;95(11):1474-82.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Biochemical profiling of anti-HIV prodrug Elsulfavirine (Elpida(?)) and its active form VM1500A against a panel of twelve human carbonic anhydrase isoforms. J Enzyme Inhib Med Chem. 2021 Dec;36(1):1056-1060.
• [7] In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells. J Immunotoxicol. 2009 Dec;6(4):243-8.
• [8] Targeting telomerase-expressing cancer cells. J Cell Mol Med. 2011 Jul;15(7):1433-42.
• [9] Clinical pipeline report, company report or official report of Vaxon-biotech.
• [10] Telomerase immunity from bench to bedside: round one. J Transl Med. 2007 Feb 26;5:12.
• [11] Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003 Jun;135(6):590-2.
• [12] Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):285-92.